Presentation – Management

Adocia Management

ADOCIA is managed by a Committee composed of four members: Gérard Soula, CEO, Valérie Danaguezian, CFO, Olivier Soula, Deputy General Manager – R&D Director, Rémi Soula, Business Development and Intellectual Property Director.

PhD, MBA – President and CEO

Gérard Soula, MBA - President & CEO of ADOCIA

Gérard Soula, PhD, MBA

Gerard Soula holds a MBA from IAE (Aix Marseille) and a Ph.D. in Organic chemistry, graduated in IAE. He founded Flamel Technologies (in 1990), a biotech Company specialized in Drug Delivery and listed on Nasdaq. He was there CEO and Director of Research until June 2005. When he left, Flamel had 250 employees, $100M cash in bank and a market capitalization of $500M. Flamel Technologies’ success is based on the performances of its platforms, Micropump and Medusa. Furthermore, Gérard Soula has a strong track record in negotiating license agreements in innovating technologies with big pharma groups (Novo Nordisk, Bristol Myers Squibb, GlaxoSmithKline etc). He is co-author of more than 120 patents.  

Chief Financial Officer

Valérie Danaguezian, CFO

Valérie Danaguezian, CFO


Valérie Danaguezian worked for 4 years as an external auditor at Calan Ramolino & Associés (Deloitte & Touche). In 1991, she joined Sanofi Pasteur where she was in charge of the financial consolidation of the Group; she was then promoted as Director of R&D controlling. In 2003, she joined Flamel Technologies as Financial Director, a position she held for 3 years.  She has joined ADOCIA in 2006 as Financial Director and member of ADOCIA Committee management.

PhD, MBA – Deputy General Manager – R&D Director

Olivier Soula, PhD, MBA

Olivier Soula, PhD, MBA


Olivier Soula holds a Ph.D. in polymer science, graduated of ENSIC Mulhouse, and an MBA from IAE, Lyon. He worked for 8 years at Flamel Technologies as Director of the Nanotechnologies department. He led the development of Medusa, a prolonged release platform of therapeutic proteins and successfully conducted clinical trials for three of those projects. Olivier is co-author of nearly 40 patents relating to protein delivery. He has worked for 16 years on insulin formulation. 

PhD, MBA – Business Development and Intellectual Property Director

Rémi Soula, PhD, MBA


Rémi Soula holds a PhD in polymer science and a MBA from HEC Paris. He did his Post-Doc at the Max Planck Institute in Postdam. Rémi spent 3 years at Flamel Technologies as senior in Polymer Synthesis. Today, as Director of Business Development and Intellectual Property Director at ADOCIA, he is the co-author of more of 30 patents and 6 scientific publications.